Seeking Alpha

Galena Biopharma, Inc. (GALE)

  • Jan. 13, 2014, 10:21 AM
    • Galena Biopharma (GALE +13.7%) rallies on news the company is buying Mills Pharmaceuticals, giving GALE rights to GALE-401 (CR anagrelide), a treatment for Essential Thrombocythemia.
    • In GALE's estimation, the drug "meets the qualifications for orphan drug status [and] has an estimated peak market size of approximately $200M in the U.S."
    • The company says a Phase 2 study should begin in "mid-2014."
    • GALE made an upfront payment to Mills' owners who are also eligible for stock grants and a milestone payment, the latter is contingent upon FDA approval of an NDA for '401. (PR)
Visit Seeking Alpha's
GALE vs. ETF Alternatives
Company Description
Galena Biopharma Inc, is a biopharmaceutical company focused on developing and commercializing, targeted treatments that address unmet medical needs to advance cancer care.
Sector: Healthcare
Industry: Biotechnology
Country: United States